# Mayo Clinic

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mayo-clinic
Canonical HTML page: https://getbiobrief.com/entity/mayo-clinic

## Timeline

- **2026-07-14**: First in-orbit medical X-ray — A crewmember aboard a commercial spaceflight captures a diagnostic hand radiograph on day L+1, confirming that diagnostic imaging is possible in sustained orbital microgravity.
- **2026-Q3 (estimated)**: Clinical Milestones — Anticipated updates on Phase 1/2 trial progress for MT-125 in GBM.
- **2026-03-24**: BioFlorida Showcase — Presentation in the Cornerstone Session: Innovation at BioFlorida.
- **2026-03-10**: Investival Showcase — Participation in the South Florida - The Rising Life Science Hub event.
- **2026-03-09**: Conference Announcement — Invited to present at two major South Florida life sciences events.
- **2026-02-15**: Partnering Circuit — Presented at BioCom California Global Life Science Partnering Conference.
- **2022**: Parabolic flight test — Dr. Gifford's team successfully obtains a digital X-ray of a hand in microgravity during a parabolic flight, proving the feasibility of portable X-ray in weightlessness.

## Recent coverage (5 stories)

### ALS patient's 1-year decline spotlights 90% sporadic case urgency for biopharma
2026-08-07 05:59:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The devastating speed of Chris Johnson’s sporadic ALS—from an elite athlete to eye-controlled communication in a year—exposes the profound unmet need in neurodegenerative drug development. With current therapies offering only months of survival benefit, the biopharma sector faces immense pressure to deliver disease-modifying treatments.
Full story: https://getbiobrief.com/story/chris-johnson-als-diagnosis-biopharma-opportunity

### Mayo Clinic-led X-ray feat accelerates low-radiation portable device innovation
2026-07-20 02:37:53 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

The first medical X-ray in space was captured with a compact, battery-powered digital radiography unit, validating a new wave of devices that minimize radiation while delivering diagnostic images. Biotech investors and device manufacturers are eyeing dual-use applications in telehealth and expedition medicine.
Full story: https://getbiobrief.com/story/low-radiation-portable-x-ray-mayo-clinic-space

### Cognivia-Mayo Collaboration Targets 3 Behavioral Drivers to Improve Trial Retention
2026-07-12 15:20:14 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Cognivia and Mayo Clinic are zeroing in on non-adherence, missed appointments, and trial dropout—three behavioral factors that inflate clinical trial costs and delay drug development. By making patient behavior measurable, the partnership could help biopharma sponsors de-risk studies and improve real-world evidence.
Full story: https://getbiobrief.com/story/cognivia-mayo-behavioral-intelligence-bio

### Myosin Therapeutics to Detail Mechanical Oncology Strategy at Florida Summits
2026-03-10 01:08:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Myosin Therapeutics is set to present its first-in-class NMIIA/IIB inhibitor, MT-125, at two major South Florida life sciences conferences this March. The company's unique approach targets the physical mechanics of glioblastoma cells, offering a potential solution to traditional drug resistance.
Full story: https://getbiobrief.com/story/myosin-therapeutics-mt125-glioblastoma-conferences

### Merck and Mayo Clinic Launch AI-Driven Drug Discovery Collaboration
2026-02-19 11:27:00 · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck and Mayo Clinic have entered a multi-year research and development collaboration to leverage artificial intelligence for drug discovery and personalized patient care. The partnership integrates Merck's pharmaceutical expertise with Mayo Clinic's clinical data and AI capabilities to accelerate the development of targeted therapies.
Full story: https://getbiobrief.com/story/merck-mayo-clinic-ai-drug-discovery-partnership

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.